Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Spain
Institut Catalá d'Oncologia (ICO) BADALONA, Badalona, Catalonia Hospital Universitario Valle Hebron, Barcelona, Catalonia Hospital Clinic de Barcelona, Barcelona, Catalonia Institut Catalá d'Oncologia (ICO) Hospitalet, L'Hospitalet de Llobregat, Catalonia Complejo Hospitalario de Navarra, Pamplona, Navarre